Meet the Network: Bart de Boer

The Life Sciences & Health ecosystem within the Rotterdam region consists of a wide network of companies and other organizations, such as educational institutes and healthcare providers, innovating in healthcare. As Rotterdam Square, we would like you to get to know our partners in this network. This time we introduce to you: Bart de Boer, CEO at Delta Diagnostics.

Could you first introduce yourself?

My name is Bart de Boer, and I am a graduate of Electrical Engineering from Eindhoven University of Technology. I have been active in biosensing for over 15 years. My career began at Philips Research, delving into magneto-resistive biosensors, and later transitioned to TNO, where I honed my skills in integrated optical biosensors. In 2018, I co-founded Delta Diagnostics to bring our innovative biosensing technology from TNO to the market. As a holder of over 40 patents, I hope to put my expertise to work to advance biomedical sensor systems and help shape the future of biosensing technology.

What does Delta Diagnostics do?

Delta Diagnostics originated as a spinoff from TNO. At TNO, we were deeply involved in developing label-free biosensing technology. Early on, I realized this technology had immense potential beyond academics. It could revolutionize the life sciences industry. That’s when the idea of Delta Diagnostics was born – to commercialize this technology and make a tangible impact on researchers’ work globally.

Our primary focus is on simplifying the detection of biomolecules using photonic-integrated chips. This approach is cost-effective and allows for multiplexing, enabling the simultaneous analysis of multiple biomolecules. This capability is crucial for accelerating research and development in various fields within life sciences.

Securing Series A funding will accelerate the launch of our first product, the DeltaOne. The DeltaOne is the culmination of our efforts to create a high-sensitivity, label-free biosensing instrument designed to meet the needs of today’s scientists who require faster and more comprehensive answers. The DeltaOne will significantly expedite research, opening new possibilities in various life sciences disciplines.

What do you look for within the Life Sciences & Health network?

The future is bright. We aim to continue innovating and pushing the boundaries of biosensing technology. We’re also expanding our team, looking for individuals who share our passion for making a difference in the life sciences. Ultimately, we aim to be at the forefront of biosensing innovation, contributing significantly to the field.

Date: February 5, 2024